Navigation Links
New PLATO Sub-Analysis of CABG Patients Presented at ACC

ATLANTA, March 16 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced results of a new analysis of the PLATO (A Study of PLATelet Inhibition and Patient Outcomes) study which showed there were fewer deaths in patients with acute coronary syndromes (ACS) who took the investigational oral antiplatelet ticagrelor (BRILINTA™/BRILIQUE™) within seven days prior to having heart bypass surgery (coronary artery bypass graft, CABG) compared to those who took clopidogrel.(1) These data were presented today at the American College of Cardiology (ACC) meeting in Atlanta, Georgia.

"The CABG sub-analysis represents current clinical management of patients with ACS,"(1) said Dr. Claes Held, PhD, Associate Professor of Cardiology at the Uppsala Clinical Research Center and Department of Cardiology, and the sub-study's lead researcher.  "The effects of ticagrelor compared to clopidogrel showed a reduction of total mortality by 51% and CV death by 48%."(1)

This analysis included 1261 patients who were on study medication up to seven days prior to stopping study medication due to the need for urgent CABG surgery at any time after their ACS event.(1) The patients randomized to ticagrelor had a significantly lower rate of total and CV death than those randomized to clopidogrel treatment:

  • Total mortality was reduced by 51% (RRR; p<0.01) with ticagrelor (4.6% of 632) compared to clopidogrel (9.2% of 629)(1)
  • CV death was reduced by 48% (RRR; p<0.01) with ticagrelor (4.0% of 632) compared to clopidogrel (7.5% of 629)(1)
  • Rate of the primary endpoint (composite of CV death, myocardial infarction, or stroke) from the time of CABG was 10.5% (66/632) with ticagrelor and 12.6% (79/629) with clopidogrel (HR 0.84; CI 0.60-1.16, p=0.29)(1)

Additionally, there was no significant difference in CABG-related major bleeding for ticagrelor compared to clopidogrel,(1) according to both the PLATO and TIMI bleeding criteria respectively (81% for ticagrelor vs. 80% for clopidogrel, and 59% for ticagrelor vs. 58% for clopidogrel for PLATO-defined and TIMI-defined, respectively).

"These treatment comparisons were consistent with the effects seen in the overall PLATO trial," said Dr. Claes Held.(1,2)

About CABG (Coronary Artery Bypass Grafting)

CABG surgery is advised for certain ACS patients, including those who are not candidates for percutaneous coronary intervention (PCI). It is not always known which ACS patients will be advised for CABG surgery at the time of initiating oral antiplatelet therapy.(3) These patients have significant narrowing and blockages of the heart arteries (coronary artery disease).(4) CABG is a type of heart surgery that reroutes, or "bypasses," blood around clogged arteries to improve blood flow and oxygen to the heart.(5)

About PLATO CABG analysis

In the PLATO study, a double-dummy, double-blind randomized trial comparing ticagrelor plus aspirin with clopidogrel plus aspirin in patients with ACS, 1899 patients underwent CABG during the trial.(1) The trial recommended administration of ticagrelor/placebo-clopidogrel to be withheld for 24-72 hours and clopidogrel/placebo-ticagrelor for 5 days prior to CABG surgery. In the exploratory analysis, 1261 patients received study-drug up to seven days prior to CABG surgery.(1) The analysis counted events occurring from after the CABG procedure until the end of the study.(1)

Primary results from PLATO were presented at the European Society of Cardiology and simultaneously published in The New England Journal of Medicine in August 2009.(2)


Ticagrelor (BRILINTA™/BRILIQUE™) is an investigational oral antiplatelet treatment for ACS. Ticagrelor, a cyclo-pentyl-triazolo-pyrimidines (CPTP), is in a chemical class of anti-platelet agents that works differently than thienopyridines, such as clopidogrel and prasugrel, by binding reversibly to the P2Y12 receptor. Ticagrelor is the first reversibly binding oral ADP receptor antagonist.

Ticagrelor is currently under regulatory review in the US and in Europe. BRILINTA and BRILIQUE are trademarks of the AstraZeneca group of companies.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of $32.8 billion in 2009. In the United States, AstraZeneca is a $14.8 billion healthcare business.

For more information about AstraZeneca in the US or our AZ&Me™ Prescription Savings programs, please visit: or call 1-800-AZandMe (292-6363).


(1)Held. Ticagrelor Versus Clopidogrel In Patients With Acute Coronary Syndromes Treated With Coronary Artery Bypass Surgery: Results from The Plato Trial. Presented at 59th Annual Scientific Session, March 16, 2010; Atlanta Georgia. ACC Abstract Number 10-A-9909-ACC.

(2) Wallentin L, Becker R, et al. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med 2009; 361: 1-13.

(3) Kushner, F., Hand, M., et al. 2009 Focused Updates: ACC/ AHA Guidelines for the Management of Patients with ST-Elevation Myocardial Infection (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009; 120: 2271-2306.

(4) American Heart Association.  Acute Coronary Syndrome.  Available at: Accessed on February 24, 2010.

(5) American Heart Association.  Cardiac Procedures and Surgeries at a glance.  Available at: Accessed on February 24, 2010.

SOURCE AstraZeneca

Back to top



SOURCE AstraZeneca
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ticagrelor Reduced Cardiovascular Deaths and Heart Attacks in ACS Patients Undergoing Heart Procedures: New Data from PLATO Trial
2. Medco, Mayo Clinic Study Reveals Using a Simple Genetic Test Reduces Hospitalization Rates by Nearly a Third for Patients on Widely Prescribed Blood Thinner
3. Study Shows Superior Efficacy for TAXUS(R) Express(R) Stents at One Year Compared to Bare-Metal Stents in Diabetic Patients Experiencing Heart Attack
4. Savient Resubmits Biologics License Application for KRYSTEXXA(TM) (pegloticase) for the Treatment of Chronic Gout in Patients Refractory to Conventional Therapy
5. Minimally Invasive Heart Valve Therapy Improves Heart Function, Quality of Life for Mitral Regurgitation Patients
6. New Data Demonstrates Abbotts Investigational MitraClip(R) System Has Potential to be a Valuable Treatment Option for Patients With Mitral Regurgitation, the Most Common Heart Valve Condition
7. An Acute Migraine Therapy That is Not Contraindicated in Patients With a History of Vascular Disease Would Earn a 45 Percent Patient Share in the United States, According to Surveyed Neurologists
8. Genomic Health Announces Publication of Study Using Oncotype DX(R) in Node-Negative and Node-Positive Breast Cancer Patients Treated With Aromatase Inhibitors
9. Chronically Ill Patients Find Help Paying For Medicines
10. ISIS Initiates Phase 1 Clinical Trial of ISIS-SOD1Rx in Patients With ALS
11. Dendreon Presents Updated IMPACT Results Confirming PROVENGE Improves Overall Survival in Patients With Metastatic Castrate-Resistant Prostate Cancer
Post Your Comments:
(Date:11/24/2015)... , November 25, 2015 ... due to repeated failure of IVF cycles. After failure ... was totally dejected and had lost all hopes that she would be able ... Indian miracle child conceived after failure of over 15 ... abroad (UK) before they decided to take one last attempt with ...
(Date:11/24/2015)... SAN CARLOS, Calif. , Nov. 24, ... ), a leader in non-invasive genetic testing ... today announced that it will present at ... Conference in New York on Wednesday, December 2, 2015 at 1:00 p.m. ... discuss the Company,s financial results, business activities ...
(Date:11/24/2015)... /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") ... the first patient has been enrolled in ESSA,s Phase ... metastatic castration-resistant prostate cancer ("mCRPC"). the ... the United States and Canada.  ... trial, ESSA intends to demonstrate the safety, tolerability, maximum ...
Breaking Medicine Technology:
(Date:11/25/2015)... , ... November 25, 2015 , ... On November 10, ... States District Court of Connecticut on behalf of a home health care worker who ... current or former home health care workers employed by Humana, Inc., Humana at Home, ...
(Date:11/25/2015)... ... , ... On November 25, 2015, officials of Narconon Arrowhead , the ... of a new cutting edge recovery program that has been 50 years in the ... alcohol-addicted individuals with the purpose to free addicts from the symptoms and negative behaviors ...
(Date:11/25/2015)... ... , ... SCOTTSDALE, AZ) - Today, Dr. Todd C. ... and non-surgical treatments, announced the expansion of his private practice capabilities with the ... Highly trained and nationally recognized for his natural approach, Dr. Todd Hobgood serves ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... Today, ... on our nation’s roadways has dropped below 10,000 for the first time since 2011. ... in 2013. , According to data released by the National Highway Traffic Safety Administration ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... of philanthropic seniors, is resulting in a way for homeless people to have ... Schaumburg have launched a new initiative whereby they are repurposing plastic bags into ...
Breaking Medicine News(10 mins):